Health CareHealth Care Equipment & Services
  • Price (USD)57.86
  • Today's Change0.89 / 1.56%
  • Shares traded3.01m
  • 1 Year change19.92%
  • Beta1.4579
Data delayed at least 15 minutes, as of Jul 02 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

  • Revenue in USD (TTM)3.32bn
  • Net income in USD452.80m
  • Incorporated1990
  • Employees6.48k
  • Location
    Hologic Inc250 Campus DrMARLBOROUGH 01752-3020United StatesUSA
  • Phone+1 (508) 263-2900
  • Fax+1 (302) 655-5049
  • Websitehttps://www.hologic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Henry Schein, Inc.10.05bn712.82m8.43bn19.00k12.192.8311.640.83874.854.8668.3620.881.375.168.41529,179.307.246.7512.1012.0730.6929.675.284.851.0426.110.25930.006.03-0.754967.218.50-1.48--
DENTSPLY SIRONA Inc3.96bn83.80m9.68bn15.20k120.472.0724.012.450.36670.366717.7221.390.4753.025.79260,348.701.01-3.841.13-4.2553.9153.942.12-8.671.36--0.2367--1.086.63125.90-
Varian Medical Systems, Inc.3.33bn235.40m11.11bn10.06k47.695.9732.583.342.572.5236.2920.520.86063.493.27330,759.306.108.5810.6015.0043.2742.577.0910.950.9729--0.22160.0010.481.12-16.66-5.88-8.34--
ABIOMED, Inc.840.88m203.01m11.88bn1.54k59.5811.1553.1914.134.434.4318.3623.670.74061.779.58547,449.3017.8819.0919.9721.4382.0183.2024.1423.024.14--
Masimo Corporation975.80m211.35m12.54bn1.60k62.8410.0153.1912.853.693.6917.0323.160.73542.997.17609,873.8015.9322.0917.7926.7667.9666.5421.6625.095.49--
Steris PLC3.03bn407.61m13.08bn13.00k32.363.8521.624.324.764.7635.3939.960.57747.505.27233,145.807.774.978.585.4443.5541.4813.459.091.9114.790.252541.258.9410.3734.0624.7220.2710.01
Insulet Corporation776.65m5.12m13.16bn1.35k2,493.31214.94357.8316.950.08070.080712.390.93570.75373.269.81575,292.600.4971-3.140.564-3.6264.4461.420.6595-4.193.421.460.9384--30.9326.12252.37--71.60--
Hologic, Inc.3.32bn452.80m14.94bn6.48k34.387.1617.254.491.681.6812.388.080.49823.725.76513,260.306.761.498.341.7852.7553.1113.563.701.044.970.6310.004.645.8856.59--7.21--
Cooper Companies Inc2.54bn337.30m15.47bn12.00k42.953.9325.036.096.756.8750.9973.880.39991.676.65211,841.705.316.606.287.4465.1363.1113.2715.050.58326.940.34370.87774.769.0930.0111.304.180.00
West Pharmaceutical Services Inc.1.89bn260.60m16.91bn8.20k66.5111.3547.718.963.453.4525.0220.250.88165.295.80230,231.7011.709.4813.7711.2033.1532.4913.2710.892.11--0.14721.647.135.3018.2513.722.438.27
Teleflex Incorporated2.61bn551.22m17.09bn14.40k31.515.5622.276.5411.6811.7055.3966.200.40292.426.39181,418.108.505.519.156.1856.6755.1021.1012.852.387.860.43821.636.007.12135.1919.408.730.00
Align Technology, Inc.2.41bn1.89bn22.05bn14.53k11.747.7311.199.1523.8523.8530.2436.220.77717.104.76165,780.3061.0618.6084.4226.4172.0874.1678.5719.471.60--0.000.0022.3925.8710.6324.8744.10--
Data as of Jul 02 2020. Currency figures normalised to Hologic Inc's reporting currency: US Dollar USD

Institutional shareholders

51.17%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202043.90m17.00%
The Vanguard Group, Inc.as of 31 Mar 202029.36m11.37%
BlackRock Fund Advisorsas of 31 Mar 202014.91m5.77%
SSgA Funds Management, Inc.as of 31 Mar 202011.58m4.49%
Fidelity Management & Research Co. LLCas of 31 Mar 20207.80m3.02%
Wellington Management Co. LLPas of 31 Mar 20206.42m2.49%
American Century Investment Management, Inc.as of 31 Mar 20205.84m2.26%
Geode Capital Management LLCas of 31 Mar 20204.70m1.82%
Glenview Capital Management LLCas of 31 Mar 20203.91m1.52%
Parnassus Investmentsas of 31 Mar 20203.71m1.44%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.